Closing the Oral Drug Gap
Patients are driving the push away from needles, and there are a number of novel approaches attempting to solve the difficult task of transforming biologics into orally administered treatments.
AstraZeneca invests in oral biologics startup Rani Therapeutics
AstraZeneca joins other notable investors like GV (Google Ventures) and Novartis to fund Rani Therapeutics' oral biologics.
presented by
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!